{"id":664410,"date":"2026-06-29T14:12:10","date_gmt":"2026-06-29T14:12:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/664410\/"},"modified":"2026-06-29T14:12:10","modified_gmt":"2026-06-29T14:12:10","slug":"stroke-glp-1s-like-ozempic-mounjaro-may-reduce-cardiovascular-risks","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/664410\/","title":{"rendered":"Stroke: GLP-1s Like Ozempic, Mounjaro May Reduce Cardiovascular Risks"},"content":{"rendered":"

\"GLP-1Share on Pinterest<\/a>A growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline\/Munro\/Getty ImagesGLP-1 medications like Ozempic and Wegovy help protect heart health, but stopping the medications may reduce the protective effects.Some research suggests that GLP-1s containing tirzepatide (Zepbound, Mounjaro) may help lower the risk of further complications in people with cardiovascular disease.Other research suggests that GLP-1s may help reduce thromboembolic events, such as deep vein thrombosis (DVT), in people with obesity and autoimmune diseases.<\/p>\n

GLP-1 medications were originally developed for the management of type 2 diabetes<\/a>.<\/p>\n

A large body of evidence shows that GLP-1s offer health benefits beyond diabetes and weight loss.<\/p>\n

Recent research published in BMJ Medicine<\/a> suggests that GLP-1 medications may support heart health, with cardiovascular benefits increasing with longer duration of use. However, stopping the medication may reduce heart-protective benefits. <\/p>\n

The studies have not yet been published in a peer-reviewed scientific journal, but a news release<\/a> detailed some of these findings.<\/p>\n

\u201cThese findings are consistent with what we are seeing broadly that medications like tirzepatide are not just weight loss drugs but have meaningful cardiometabolic benefits,\u201d said Kevin Shah<\/a>, MD, a cardiologist and the program director of Heart Failure Outreach at MemorialCare Heart & Vascular Institute at the Long Beach Medical Center, in a previous interview<\/a> with Healthline. Shah wasn\u2019t involved in the studies.<\/p>\n

GLP-1 medications may reduce the risk of heart disease. However, once you stop taking the medication, the protection may be reversed, according to research published in BMJ Medicine<\/a> in March.<\/p>\n

The research suggests that, while continued use may increase heart benefits over time, stopping the medication may reduce or reverse those benefits. <\/p>\n

The study followed 132,551 people taking GLP-1 medication and 201,136 people taking sulfonylurea for 3 years to treat diabetes. It noted that 26.36% of people discontinued GLP-1 treatment, most commonly during the first year.<\/p>\n

As the study found that GLP-1 medications are more likely to provide heart health protection over time, stopping treatment earlier means they are less likely to offer these benefits.<\/p>\n

\u201cThe main message is that GLP-1 therapy behaves more like a long-term risk-reduction treatment than a short-term fix,\u201d said Robert Glatter<\/a>, MD, attending physician in the Department of Emergency Medicine at Lenox Hill Hospital in New York City, and assistant professor of Emergency Medicine at Zucker School of Medicine at Hofstra\/ Northwell, in a previous interview<\/a>. Glatter was not involved in the study.<\/p>\n

\u201cThe study reinforces a broader lesson in chronic disease management: benefits that accumulate slowly can be lost surprisingly fast when treatment is interrupted, so persistence and follow-up truly matter,\u201d he told Healthline.<\/p>\n

\u201cGLP-1 receptor agonists are increasingly recognized as having effects that extend beyond weight loss and glucose control,\u201d said Christopher Yi<\/a>, MD, board certified vascular surgeon at MemorialCare Orange Coast Medical Center in Fountain Valley, CA. Yi wasn\u2019t involved in the study.<\/p>\n

\u201cThey reduce systemic inflammation, improve metabolic health, and may improve endothelial function \u2014 all mechanisms that could plausibly reduce thromboembolic risk,\u201d Yi told Healthline.<\/p>\n

\u201cWhat I found especially noteworthy is that the reduction appeared stronger for venous thromboembolic events than for some arterial cardiovascular outcomes such as myocardial infarction<\/a>. The authors suggest that venous thrombosis may be more directly influenced by inflammation and obesity-related hypercoagulability<\/a>, which could make it more responsive to GLP-1 therapy,\u201d Yi continued.<\/p>\n

The research article noted the following findings:<\/p>\n

44% lower all-cause mortality31% lower risk of pulmonary embolism17% lower risk of venous thromboembolism21% lower emergency department visits<\/p>\n

Earlier studies<\/a> have shown similar results in people with diabetes<\/a> and chronic kidney disease (CKD)<\/a>. The authors of this study said this may be attributed to improved cardiometabolic parameters, which lead to fewer sudden health problems and subsequent emergency room visits. <\/p>\n

Cardiometabolic parameters are measurements of the health of the heart, blood vessels, and metabolic system.<\/p>\n

\u201cThe most striking result in the paper may actually be the 44% reduction in all-cause mortality,\u201d Yi said. <\/p>\n

\u201cWhile observational findings of that magnitude should always be interpreted cautiously, it raises an important hypothesis that GLP-1 therapies may be addressing several interconnected disease pathways simultaneously \u2014 obesity, inflammation, cardiometabolic dysfunction, and possibly thrombosis,\u201d he continued.<\/p>\n

\u201cAt the same time, I would emphasize that the findings are hypothesis-generating. They are exciting and biologically plausible, but randomized trials specifically designed to evaluate thromboembolic outcomes would be needed before GLP-1s could be formally recommended primarily for VTE or PE prevention,\u201d Yi said.<\/p>\n","protected":false},"excerpt":{"rendered":"Share on PinterestA growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline\/Munro\/Getty ImagesGLP-1…\n","protected":false},"author":2,"featured_media":664411,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[102,6591,56,54,55],"class_list":["post-664410","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-medication","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/664410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=664410"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/664410\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/664411"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=664410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=664410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=664410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}